Trial Profile
A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jan 2021
Price :
$35
*
At a glance
- Drugs Girentuximab I-124 (Primary)
- Indications Renal cancer; Renal cell carcinoma
- Focus Diagnostic use
- Acronyms REDECT
- Sponsors Heidelberg Pharma AG; WILEX Inc
- 20 Jun 2014 New trial record